Microdosing THC for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Microdosing THC for Health & Longevity

Created on 09/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Microdosing means taking tiny amounts of cannabis's main intoxicating compound, below noticeable intoxication, hoping to ease pain, stress or poor sleep and possibly slow brain aging. Human support is clearest for modest nerve-pain relief; sleep effects are mixed, and brain-aging benefit is animal-only. Dizziness is common at prescription doses, regular use risks dependence, and frequent use is linked to heart attack and stroke; risks at true microdoses are largely unmeasured. (Full Review)

Protocol

Standard microdose protocol (Dustin Sulak)
1 mg oral, +1 mg every few days
After 48 hours without cannabis; maintenance typically 1–3 mg once or twice daily
Best time of day
Evening
Suits sleep and limits daytime impairment; small daytime doses (1 mg or less) on days without driving
Age considerations
Over 65: 0.5–1 mg starting dose
Protocols increase no faster than weekly; starting with 5–10 mg edible products has led to emergency visits in frail older adults
Time to effect
Pain and sleep effects
Within days
Any effect on brain aging is untested in people
Inhaled THC
Minutes
Onset suits breakthrough pain; effects last 2–4 hours
Oral THC
30–120 minutes
Effects last 4–8 hours

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • People under 25
  • Personal or first-degree family history of schizophrenia, other psychotic disorders or bipolar I disorder
  • Current or past substance use disorder, including cannabis use disorder
  • Recent heart attack or stroke (<90 days), unstable angina, symptomatic arrhythmia, or uncontrolled blood pressure (>160/100 mmHg)
  • Severe liver impairment (Child-Pugh Class C)
  • Older adults with two or more falls in the past year
  • Pilots, commercial drivers and other safety-sensitive workers under zero-tolerance drug testing
    •
Key Interactions
  • CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Caution
  • CYP2C9 inhibitors (fluconazole, amiodarone, sulfamethoxazole): Caution
  • Enzyme inducers (rifampin, carbamazepine, phenytoin, St. John's wort): Monitor
  • Central nervous system depressants (diazepam, alprazolam, oxycodone, zolpidem, gabapentin, alcohol): Caution
  • Warfarin: Monitor
  • Stimulants and anticholinergics (amphetamine, amitriptyline, atropine): Caution
  • Over-the-counter medications (diphenhydramine, doxylamine, pseudoephedrine, dextromethorphan): Caution
  • Supplements with additive sedation (kava, valerian, melatonin, high-dose magnesium): Monitor
  • Cannabidiol and hemp extracts: Monitor
  • Other interventions (driving, operating machinery, heat exposure such as sauna): Caution
    •

Risk & Side Effects

  • High: Short-term impairment of attention, coordination and driving; dizziness, drowsiness and dry mouth; anxiety, paranoia and psychotic-like symptoms
    •
  • Medium: Dependence, cannabis use disorder and withdrawal; heart attack, stroke and rapid heart rate; chronic psychotic disorder in susceptible people; blood pressure drop and fainting on standing; cough, phlegm and wheezing with smoked cannabis; later depression with regular use
    •
  • Low: Balance problems and falls in older adults; long-term cognitive decline and dementia; cannabinoid hyperemesis syndrome
    •
  • Speculative: Faster epigenetic aging; impaired learning in younger brains
    •

Monitoring

Marker Target Why
Resting heart rate 50–70 bpm Detects THC-induced fast heart rate
Blood pressure, seated and standing Below 120/80 mmHg; standing drop under 20/10 mmHg Cardiovascular and fainting risk
Fasting glucose 75–90 mg/dL Metabolic baseline
Fasting insulin 2–6 µIU/mL Tracks insulin sensitivity
HbA1c Below 5.4% Three-month glucose average
ALT and AST ALT below 25 U/L; AST below 25 U/L Liver capacity to process THC
INR (only if on warfarin) Individual therapeutic target, usually 2.0–3.0 Detects warfarin interaction
Waist circumference Below 90 cm men, below 80 cm women Tracks appetite-driven weight change
MoCA score 26–30 Detects cognitive change
PHQ-9 and GAD-7 0–4 on each Tracks mood and anxiety
CUDIT-R 0–7 Screens for problematic use
Sleep stages (wearable or sleep study) No established target; track change from own baseline in total sleep and REM share Detects REM suppression

Cadence: Pulse and blood pressure 1–2 hours after the first three doses and again at 2 weeks; questionnaires at 3 months; then blood tests, cognitive screening and questionnaires every 6–12 months; INR within one week of any THC change

Qualitative Assessment

  • Sleep quality and ease of falling asleep
  • Pain intensity on a 0–10 scale
  • Daytime stress and mood
  • Next-morning grogginess or slowed thinking
  • Mental clarity and short-term memory
  • Cravings, tolerance or a sense of needing a higher dose
  • Palpitations or dizziness on standing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.